Background
To evaluate the effects of hormon replacement therapy and pamidronate on the bone mineral density and serum osteocalcin in the postmenopausal women.
Methods
This prospective randomized clinical trial examined the effects of oral pamidronate and conjugated equine estrogen, in combination and seperately, on BMD and serum osteocalcin in 140 women. Treatment included pamidronate (group I, n=50), or conjugated equine estrogen (group II, n=50), conjugated equine estrogen plus pamidronate (group III, n=40) for 12 months. The bone density measurement was performed at months 6 and 12 months at the lumbar spine. Serum osteocalcin was also measured every six months.
Results
BMD of lumbar spine, it increased significantly during the treatment in Group I, Group II, and Group III (p<0.005). Serum osteocalcin in Group I, Group II and Group III decreased signifiantly at 12 months of treatment (p<0.005).
Conclusion
The combination treatment with pamidronate and conjugated equine estrogen is more effective in postmenopausal women with osteoporosis by decreasing the bone biochemical marker and by increasing the BMD.
